Photo from MSKCC/LinkedIn
May 10, 2024, 16:58
The first tumor-agnostic study of a HER2-directed antibody-drug conjugate – MSKCC
Memorial Sloan Kettering Cancer Center (MSKCC) shared on LinkedIn:
“Lead author Dr. Bob Li, a thoracic oncologist from Memorial Sloan Kettering Cancer Center, and international colleagues published the first tumor-agnostic study of a HER2-directed antibody-drug conjugate in patients with solid tumors harboring activating HER2 mutations in Lancet Oncology in May 2024.
The results showed that trastuzumab deruxtecan provided encouraging and durable anti-tumor activity. Dr. Li first presented results about this study at ESMO 2023. Read more.” .
